all age group

[키워드] ACE-2 receptor acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 all age group all age groups Alpha Antibody-dependent enhancement approach approval approved attenuated vaccine Attenuated Virus B.1.1.7 B.1.351 B.1.429 B.1.525 B.1.617 B.1.617.2 BCG being Beta booster dose candidate vaccine caused CD8 challenge China city clinical development clinical trial combating Compliance contrary Coronaviridae family coronavirus coronavirus disease Coronavirus-2 COVID-19 CTL Delta disease severity Effectiveness Efficacy elicit Emergency use Epsilon Eta Gamma herd immunity host cells immune activation immune response immune responses Immunity inactivated Inactivated Vaccines inhibit intracellular pathogen Live attenuated vaccine MOST Multiple multiple antigens multivariant vaccines Mutation mutations Neutralizing antibodies neutralizing antibody nucleic acids pandemic pathogen Phase III clinical trials platform potential limitations Prophylactic Replication Resolution RNA virus SARS CoV-2 variant SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Spike protein subunit vaccines T cell the Coronaviridae Vaccine vaccine candidate Vaccine hesitancy Vaccines variant variants Viral Viral antigen viral antigens viral entry viral spike protein viral vectors virus viruses WHO Wuhan
[DOI] 10.3389/fcimb.2021.690621 PMC 바로가기 [Article Type] Review